EXCLUSIVE: SAB Biotherapeutics Says Influenza, COVID-19 Candidates Showing Broad Efficacy Against Variants

SAB Biotherapeutics Inc SABS presented an overview of its DiversitAb polyclonal platform at the 2022 Plasma Product Biotechnology Conference.

The company said the DiversitAb platform can produce natural, specifically targeted, high-potency, fully-human polyclonal immunotherapies against various disease targets without human donors.

The company also outlined data on SAB-185 for COVID-19 and SAB-176 for seasonal and pandemic influenza showing the candidates being effective against variants of several highly mutating viruses associated with the diseases.

SAB-185 exhibited equivalent neutralization of the Munich, Alpha, Beta, Gamma variants and a variant isolated from an immunocompromised patient. 

It retained neutralization of the Delta variant AY.1 and multiple Omicron variants, with only modest losses of neutralization activity. 

Related: SAB Biotherapeutics Unveils New Data From COVID-19 Programs Reinforcing Efficacy Against Variants.

Prophylactic SAB-185 treatment protected the hamsters from death and minimized signs of infection when challenged with the variant viruses tested. 

Phase 2a trial for SAB-176 met its primary endpoint of reducing the nasopharyngeal viral load in subjects challenged with H1N1 A/California/2009-like virus. 

SAB-176 also met secondary endpoints of reducing symptoms by Day 4 and shortened the timeframe of the ability to culture virus in vitro, suggesting reduced viral shedding, and was safe and well tolerated. 

Price Action: SABS shares closed at $0.95 on Wednesday.